XNASBEAM
Market cap2.38bUSD
Dec 23, Last price
28.70USD
1D
-1.07%
1Q
15.87%
IPO
39.19%
Name
Beam Therapeutics Inc
Chart & Performance
P/E
—
P/S
6.29
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
17.03%
Rev. gr., 5y
270.63%
Revenues
378m
+520.01%
Net income
-133m
L-49.72%
CFO
-149m
L
Dividend
Feb 04, 20140.225 USD/sh
Earnings
Feb 25, 2025
Profile
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 377,709 520.01% | 60,920 17.51% | 51,844 215,916.67% | ||||
Cost of revenue | 991,575 | 421,976 | 460,750 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (613,866) | (361,056) | (408,906) | ||||
NOPBT Margin | |||||||
Operating Taxes | 1,366 | 3,410 | (29,278) | ||||
Tax Rate | |||||||
NOPAT | (615,232) | (364,466) | (379,628) | ||||
Net income | (132,527) -49.72% | (263,588) -22.78% | (341,360) 33.12% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 270,168 | 108,258 | 757,449 | ||||
BB yield | -12.86% | -3.95% | -14.80% | ||||
| Debt | |||||||
Debt current | 12,778 | 10,380 | 7,540 | ||||
Long-term debt | 332,600 | 347,630 | 277,160 | ||||
Deferred revenue | 109,888 | 202,179 | 262,303 | ||||
Other long-term liabilities | 3,021 | 13,841 | 37,167 | ||||
Net debt | (844,498) | (732,878) | (693,693) | ||||
| Cash flow | |||||||
Cash from operating activities | (149,195) | 22,527 | (66,268) | ||||
CAPEX | (33,732) | (48,951) | (46,811) | ||||
Cash from investing activities | 71,840 | (461,336) | (294,144) | ||||
Cash from financing activities | 276,448 | 111,590 | 756,141 | ||||
FCF | (618,905) | (411,623) | (441,232) | ||||
| Balance | |||||||
Cash | 1,189,876 | 1,078,134 | 965,647 | ||||
Long term investments | 12,754 | 12,746 | |||||
Excess cash | 1,170,991 | 1,087,842 | 975,801 | ||||
Stockholders' equity | (1,188,469) | (1,059,080) | 706,813 | ||||
Invested Capital | 2,455,396 | 2,187,579 | 561,745 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 77,152 | 70,015 | 64,228 | ||||
Price | 27.22 -30.40% | 39.11 -50.92% | 79.69 -2.39% | ||||
Market cap | 2,100,071 -23.31% | 2,738,299 -46.50% | 5,118,304 34.15% | ||||
EV | 1,255,573 | 2,005,421 | 5,899,064 | ||||
EBITDA | (593,854) | (346,909) | (401,455) | ||||
EV/EBITDA | |||||||
Interest | 15,297 | 9 | |||||
Interest/NOPBT | |||||||